It was shown to enhance TAM sensitivity by functioning as a competing endogenous RNA (ceRNA) for miR-182-5p, which modulates the expression and activity of FOXO3a, thereby potentially inhibiting tumor progression in hormone receptor-positive BC patients undergoing TAM therapy (Fig. 6) (Table 5) (Sang et al. 2019). Here, FOXO3 is linked to neoplasm.